101. Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer
- Author
-
Boya Deng, Lili Ren, Everett E. Vokes, Jae-Hyun Park, Taigo Kato, Tanguy Y. Seiwert, Kazuma Kiyotani, Nishant Agrawal, Tatsuo Matsuda, and Yusuke Nakamura
- Subjects
non-synonymous mutation ,0301 basic medicine ,Somatic cell ,T cell ,chemical and pharmacologic phenomena ,Biology ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Tumor-infiltrating lymphocytes ,T-cell receptor ,Cancer ,hemic and immune systems ,medicine.disease ,squamous cell carcinoma of head and neck cancer ,mismatch repair ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,MSH2 ,tumor-infiltrating lymphocytes ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,T cell receptor ,CD8 ,Research Paper - Abstract
Though adoptive tumor-infiltrating lymphocyte (TIL) therapy has been explored in clinical trials for many years, there is little information for the clonotype composition between TILs in original tumor tissues and TILs that were in vitro expanded and infused to cancer patients. To investigate the similarity/difference in TILs in original tumor tissues and those of in vitro expanded populations in squamous cell carcinoma of head and neck (SCCHN) as well as their correlation with somatic mutations in cancer cells, we performed whole exome analysis, expression profile analysis of immune-related genes, and T cell receptor (TCR) analysis of original TILs and in vitro expanded TILs in 8 surgically-resected HPV-negative fresh tumors with SCCHN. We found an unusually high number of non-synonymous somatic mutations (4290, 1779 and 901 mutations) in three SCCHN tumors, in which we identified mutations in mismatch repair genes, MSH2 or MSH4, or a DNA polymerase gene, POLE. Interestingly, dominant TCR clonotypes of expanded CD8+ TILs derived from these three tumors revealed high similarity to those in original tumors while for remaining tumors with the lower mutational load, we found that T cell clonotypes between TILs in original tumor tissues and those expanded in vitro were almost entirely different. Our findings might provide clinically useful information for identification of tumor-antigen-specific T cell clones that may lead to further improvement of adoptive TIL therapy for SCCHN patients.
- Published
- 2017